[Changes in fibrinolysis-associated parameters in HELLP syndrome].
Various parameters associated with fibrinolysis were examined in plasma and placenta tissue extract in 18 patients with HELLP syndrome (haemolysis, elevated liver enzymes, and low platelet count). A significant increase in plasma concentrations of tPA and PAl-1 was observed in the HELLP patients in comparison to 18 pregnant women of the control group (equal duration of pregnancy). In contrast, there was no difference in plasma concentrations of uPA, uPA-receptor and D-dimer. In placenta tissue extract, significant differences were found just as rarely for uPA, uPA-receptor and PAl-1 as for tPA and D-dimer. Our findings indicate, that endothelial damage with release of tPA may be involved in the pathophysiological pathway of HELLP syndrome. Increased plasma levels of PAl-1 may reflect deficient fibrinolysis resulting in impairment in microcirculation. Clinical relevance of tPA and PAl-1 plasma concentration as possible predictor of hypertensive pregnancy complications will have to be studied further.
Kolben
M
M
Frauenklinik Technischen Universität München, Klinikum rechts der Isar.
Lopens
A
A
Schmitt
M
M
Schneider
K T
KT
Graeff
H
H
D000328:Adult; D002585:Cesarean Section; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D017359:HELLP Syndrome / Q000201:enzymology*; D006801:Humans; D007231:Infant, Newborn; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011247:Pregnancy; D011956:Receptors, Cell Surface / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator; D012016:Reference Values; D010959:Tissue Plasminogen Activator / Q000097:blood; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood
D005338:Fibrin Fibrinogen Degradation Products; C524898:PLAUR protein, human; D017395:Plasminogen Activator Inhibitor 1; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; C036309:fibrin fragment D; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
Veränderungen Fibrinolyse-assoziierter Parameter bei HELLP-Syndrom.